Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
BROAD-SPECTRUM ANTIVIRAL AND CYTOCIDAL ACTIVITY OF CYCLOPENTENYLCYTOSINE, A CARBOCYCLIC NUCLEOSIDE TARGETED AT CTP SYNTHETASE

ERIK DE CLERCQ,*‡ JUNICHI MURASE§ and VICTOR E. MARQUEZ

*Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; ‡Toyo Jozo Co., Research Laboratories, Mifuku Ohito-Cho, Tagata-gun, Shizuoka-ken, 410-23, Japan; and §Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892, U.S.A.

(Received 16 October 1990; accepted 4 January 1991)

Abstract—Cyclopentenylcytosine (Ce-Cyd) is a broad-spectrum antiviral agent active against DNA viruses [herpes (cytomegalo), pox (vaccinia)], (+)RNA viruses [picorna (polio, Coxsackie, rhino), toga (Sindbis, Semlikf forest), corona], (−)RNA viruses [orthomyxo (influenza), paramyx (parainfluenza, measles), arena (Junin, Tacaribe), rhabdo (vesicular stomatitis)] and (−)RNA viruses (reo). Ce-Cyd is a more potent antiviral agent than its saturated counterpart, cyclopentylcytosine (carbodine, C-Cyd). Ce-Cyd also has potent cytocidal activity against a number of tumor cell lines. The putative target enzyme for both the antiviral and antitumor action of Ce-Cyd is assumed to be the CTP synthetase that converts UTP to CTP. In keeping with this hypothesis was the finding that the antiviral and cytocidal effects of Ce-Cyd are readily reversed by Cyd and, to a lesser extent, Urd, but not by other nucleosides such as dThd or dCyd. In contrast, pyrazofurin and 6-azauridine, two nucleoside analogues that are assumed to interfere with OMP decarboxylase, another enzyme involved in the biosynthesis of pyrimidine ribonucleotides, potentiate the cytocidal activity of Ce-Cyd. Ce-Cyd should be further pursued, as such and in combination with OMP decarboxylase inhibitors, for its therapeutic potential in the treatment of both viral and neoplastic diseases.

Various pyrimidine nucleoside analogues, i.e. 5-fluoro-2′-deoxyuridine [1], 5-iodo-2′-deoxyuridine [2], (E)-5-[(2-bromovinyl)]-2′-deoxyuridine [3], 5-ethyl-2′-deoxyuridine [4], 3′-amino-2′,3′-dideoxythymidine [5], 5-iodo-2′-deoxycytidine [6] and 5-ido-1-[(2-deoxy-2-fluoro-D-β-D-arabinofuranosyl)cytosine [7], are known as potent antiviral or antitumor agents. To make these nucleoside analogues resistant to degradation by nucleoside HO phosphorylases that cleave the N-glycosidic bond, carbocyclic derivatives of these nucleosides have been synthesized, whereby the sugar part is replaced by a cycloalkyl ring [1-7]. As a rule, these carbocyclic derivatives retained only part of the antitumor or antiviral activity of the parent compounds. Also, carbocyclic analogs, both cyclopentyl and cyclopentenyl derivatives, of the normal nucleoside cytidine have been prepared, and these derivatives, termed C-Cyd (carbodine) and Ce-Cyd respectively (Fig. 1), have proved effective as both antiviral and antitumor agents [8-11].

Ce-Cyd has shown antitumor activity in several human tumor xenografts in athymic mice; in vitro it has proved active against herpesviruses (herpes simplex, cytomegalo and varicella-zoster), vaccinia, influenza A, vesicular stomatitis virus, Japanese encephalitis virus and Punta Toro virus [11].

Both C-Cyd and Ce-Cyd are assumed to interact with CTP synthetase, the enzyme that converts UTP to CTP, after they have been phosphorylated intracellularly to the 5′-triphosphate [9,12,13]. Direct measurements with CTP synthetase from murine leukemia L1210 cells have indicated that the 5′-triphosphate of Ce-Cyd is indeed inhibitory to the enzyme [14]. The depletion of CTP pools that results from such an inhibitory effect has been held responsible for the cytocidal action of Ce-Cyd in vitro.

Fig. 1. Formulae of cyclopentenylcytosine (Ce-Cyd) and cyclopentylcytosine (C-Cyd, carbocyclic cytidine, carbodine).
vitro [12] and its antitumor activity in vivo [13]. It has not been ascertained, however, whether the antiviral action of Ce-Cyd also results from an inhibitory effect on CTP synthetase.

The present studies were undertaken to (i) delineate the antiviral activity spectrum of Ce-Cyd (in comparison with the activity spectrum of C-Cyd [15]), and to (ii) assess the influence of exogenously added cytidine and other nucleosides on both the antiviral and cytocidal action of Ce-Cyd. In agreement with previous studies [11], Ce-Cyd was found to be a highly potent inhibitor of both virus replication and tumor cell proliferation. It proved active against a remarkably broad range of RNA and DNA viruses. Both the antiviral and cytocidal action of Ce-Cyd could be reversed by Cyd, but not dThd or dCyd. Combination of Ce-Cyd with pyrazofurin or 6-azauridine, two compounds which are known to inhibit OMP decarboxylase, resulted in an enhancement of its cytocidal activity [16-19].

**MATERIALS AND METHODS**

**Compounds.** Ce-Cyd was synthesized as described by Lim et al. [10] and Marquez et al. [11]. C-Cyd (carbodine) was synthesized as described by Shealy and O'Dell [8] and provided by J. A. Montgomery (Kettering-Meyer Laboratory, Southern Research Institute, Birmingham, AL). Neplanocin A was obtained from Toyo Jozo Co. (Tagata-gun, Shizuoka-ken, Japan). Ribavirin (Virazole) was obtained from ICN Pharmaceuticals (Costa Mesa, CA). The nucleosides 2'-deoxycytidine (dCyd), uridine (Urd), 2'-deoxyuridine (dThd) and cytidine (Cyd) were obtained from the Sigma Chemical Co. (St Louis, MO). The sources of the other compounds were as follows: pyrazofurin [3-(β-D-ribofuranosyl)-4-hydroxypyrazole-5-carboxamide], Calbiochem Behring Corporation (Lucerne, Switzerland): 6-azauridine, Sigma Chemical Co.; 5-fluorouracil, Sigma Chemical Co.; and cytarabine [1-(β-D-arabinofuranosyl)cytosine], Upjohn (Puurs, Belgium).

**Radiochemicals.** The radiolabeled precursors [methyl-3H]-2'-deoxythymidine, [5-3H]uridine and [4.5-3H]leucine, used to monitor the synthesis of cellular DNA, RNA and protein, were obtained from Amersham (Amersham, U.K.). Their specific radioactivity was 40,30 and 52 Ci/mmol, respectively.

**Virus.** The origin of the viruses and the preparation of the virus stocks have been documented in previous reports: herpes simplex virus type 1 (strain KOS) [20], herpes simplex virus type 2 (strain G) [20], thymidine kinase deficient (TK-) herpes simplex virus type 1 (strain B2006) [21], cytomegalovirus (strains Davis and AD-169) [22], vaccinia virus [23], vesicular stomatitis virus [24], poliovirus type 1 [23], Coxsackie virus type B4, reovirus type 1 [24], parainfluenza virus type 3 [24], Sindbis virus [23], Semliki forest virus [24], Junin virus [25], Tacaribe virus [25], coronavirus (strain 229E) [15], rhinovirus (types 1A and 9) [26], respiratory syncytial virus (strain Long) [27], measles [SSPE (subacute sclerosing panencephalitis)], strain Niigata-1 [28], and influenza types A, B, C.

**Cells.** The cell lines used in the antiviral activity assays were: PRK (primary rabbit kidney), HEL (human embryonic lung fibroblast), HeLa (a human epithelial cell line derived from a cervix carcinoma), Vero (a simian fibroblast cell line derived from African green monkey kidney), WI-38 (human embryonic lung fibroblast), MDCK (Madin–Darby canine kidney), E6SM (human embryonic skin-muscle fibroblast), RK13 (a rabbit kidney cell line), BSC-1A (a simian epithelial cell line derived from African green monkey kidney), GBK (Georgia bovine kidney), CV-1 (a simian fibroblast cell line derived from African green monkey kidney) and L-929 (a murine fibroblast cell line originally derived from an adult C3H mouse and mutagenized with methylcholanthrene). The cell lines used in the cytocidal activity assays were, besides Vero and HeLa cells, murine leukemia (L1210), murine mammary carcinoma (FM3A), human B-lymphoblast (Raji) and human T lymphoblast (Molt/4F) cells. The cells were grown in Eagle's minimum essential medium supplemented with 10% fetal calf serum.

**Antiviral activity.** Inhibition of virus-induced cytopathogenicity was measured following well-established procedures [20, 24]. In all viral cytopathogenicity assays, the virus inoculum was 100 CICD90 per microtiter well [1 CICD90 corresponding to the virus stock dilution that proved infective for 50% of the cell cultures]. In the cytomegalovirus assays, plaque formation was measured instead of viral cytopathogenicity. In these assays the virus inoculum was 20 PFU (plaque forming units).

**Antimetabolite activity.** Inhibition of host cell macromolecule (DNA, RNA and protein synthesis) was monitored by incorporation of [methyl-3H]dThd, [5-3H]Urd and [4.5-3H]Leu, respectively, over an incubation period of 16 hr of exponentially growing (Vero) cells in the presence of varying concentrations of the test compounds.

**Cytocidal activity.** Inhibition of the proliferation of Vero, HeLa, L1210, FM3A, Raji and Molt/4F cells was assessed during their exponential growth phase and monitored by counting the number of viable cells (following staining with trypan blue). The procedure was similar to that initially described for L1210 cells [30].

**RESULTS**

Ce-Cyd was evaluated in comparison with C-Cyd [15] and two other broad-spectrum antiviral agents, neplanocin A [24] and ribavirin [31], against a wide variety of RNA and DNA viruses (Table 1). Of the four compounds, Ce-Cyd showed the most pronounced antiviral activity. Against some viruses (i.e. TK- herpes simplex, vaccinia, poliovirus, reovirus, Tacaribe, SSPE), Ce-Cyd proved effective at a 50% inhibitory concentration of ≤0.1 μg/mL, whereas normal cell morphology was not altered (at concentrations up to 400 μg/mL). Ce-Cyd was active against all viruses that are sensitive to C-Cyd, but, in addition, Ce-Cyd proved also active against picornaviruses (polio, Coxsackie, rhino) which are not sensitive to C-Cyd. Thus, the activity spectrum of Ce-Cyd includes all major virus groups (herpes (TK- herpes simplex, cytomegalovirus), pox (vaccinia), picorna (polio).
Table 1. Antiviral activity spectrum of Ce-Cyd, as compared to activity spectrum of C-Cyd, neplanocin A and ribavirin

| Virus                  | Cell | Ce-Cyd | C-Cyd | Neplanocin A | Ribavirin |
|------------------------|------|--------|-------|--------------|-----------|
| Herpes simplex 1 (KOS) | PRK  | >400   | 100†  | 20           | >400      |
| Herpes simplex 2 (G)   | PRK  | 200    | 400†  | 20           | >400      |
| TK⁻ Herpes simplex 1 (B2006) | PRK | 0.1‡ | 4‡    | 2‡           | >400‡     |
| Cytomegalovirus (Davis)| HEL  | 0.2    | ND    | 0.15         | 250       |
| Cytomegalovirus (AD-169)| HEL | 0.6    | ND    | 0.2          | 200       |
| Vaccinia               | PRK  | 0.02   | 15†   | 0.03         | 20        |
| Vesicular stomatitis   | PRK  | 0.7    | 0.07† | 300          |           |
| Polio                  | HEL  | 0.1    | >400†  | >40          | 20        |
| Coxsackie B4           | HEL  | 0.2    | >400†  | >40          | 40        |
| Reo 1                  | Vero | 0.1    | 0.7†   | 1            | 70        |
| Parainfluenza 3        | Vero | 0.2    | 6†     | 1            | 70        |
| Sindbis                | Vero | 0.2    | 0.7†   | 2            | 100       |
| Semliki forest         | Vero | 0.4    | 3†     | 7            | 40        |
| Junin                  | Vero | 0.03   | 0.2    | 0.3          | 1         |
| Tacaribe               | Vero | 0.03   | 0.3    | 0.3          | 1         |
| Corona (229E)          | WI-38| 10     | 15     | 300          |           |
| Rhino 1A               | WI-38| 10     | >100†  | 15           | 70        |
| Rhino 9                | WI-38| 2      | ND     | 10           | 70        |
| Respiratory syncytial (Long) | HEL | 0.04  | >70§    | >20§     | 6§        |
| SSPE (Niigata-1)       | Vero | 0.05† | 0.9| 6|| 8|| |
| Influenza A, B, C      | MDCK| 4.5†  | 4.5†   | >50†      | 4.5†      |
| Cytotoxicity           | PRK  | >400   | >400   | 40          | >400      |
| Cytotoxicity           | HEL  | >400   | ND     | 40          | >400      |
| Cytotoxicity           | HeLa | >400   | >400   | 40          | >400      |
| Cytotoxicity           | Vero | >400   | >400   | 40          | >400      |
| Cytotoxicity           | WI-38| >400   | >400   | 40          | >400      |

* Required to reduce virus-induced cytopathogenicity (or plaque formation (cytomegalovirus)) by 50%.

For cytotoxicity measurements, a microscopically detectable alteration of normal cell morphology was taken as the end point.

† Data taken from De Clercq et al. [15].
‡ Data taken from De Clercq et al. [21].
§ Data taken from Kawana et al. [27].
¶ Data taken from Hosoya et al. [28].
∥ Data taken from Shigeta et al. [29].
ND, not determined.

Coxsackie, rhino), toga (Sindbis, Semliki forest), corona, orthomyxo (influenza), paramyxovirus (parainfluenza), measles, arena (Junin, Tacaribe), rhabdoviridae (vesicular stomatitis) and reovirus (Table 1).

Ce-Cyd and C-Cyd were also examined for their inhibitory effect on the replication of human immunodeficiency virus type 1 (HIV-1) in (exponentially growing) MT-4 cells (a human T-lymphocyte cell line). Ce-Cyd and C-Cyd were inhibitory to the growth of MT-4 cells at an IC₅₀ of 1.2 and 50 ng/mL, respectively. They were not inhibitory to HIV-1 replication at concentrations below their IC₅₀ for host cell growth (data not shown).

The antiviral potency of antiviral agents may differ considerably depending on the choice of the cells, as has been previously noted with C-Cyd and ribavirin when evaluated for their activity against vesicular stomatitis virus in different cell lines [15]. In contrast with C-Cyd and ribavirin, however, Ce-Cyd inhibited the cytopathogenicity of vesicular stomatitis virus in all cell lines in which it was examined (Table 2). Differences between C-Cyd and Ce-Cyd were particularly striking in RK13 and BSC-1A, two cell lines in which Ce-Cyd exhibited marked antiviral activity whereas C-Cyd did not. The concentrations at which Ce-Cyd inhibited vesicular stomatitis virus in the different cell lines ranged from 0.1 to 2 µg/mL, whereas, again, no alteration of normal cell morphology was observed at C-Cyd concentrations up to 400 µg/mL.

Ce-Cyd was not toxic to resting (confluent) cell monolayers, as used in the antiviral assays (Tables 1 and 2), at concentrations up to 400 µg/mL. However, Ce-Cyd proved inhibitory to (Vero) cell DNA and RNA synthesis (as monitored by the incorporation of [methyl-³H]dThd and [⁵³S]Urd, respectively), at a concentration of 1.4 and 0.7 µg/mL, respectively (Table 3). These concentrations coincide with, or are only 10- to 100-fold higher than, the concentrations at which Ce-Cyd inhibit antiviral activity in Vero cells (Tables 1 and 2). Yet, it should be pointed out that during macromolecule synthesis the cells were in their exponential growth phase, whereas they were resting (confluent) in the antiviral activity assays.

Ce-Cyd proved inhibitory to the growth of HEL
Table 2. Activity of Ce-Cyd, C-Cyd, neplanocin A and ribavirin against vesicular stomatitis virus in different cell lines

| Cell   | Ce-Cyd (μg/mL) | C-Cyd (μg/mL) | Neplanocin A (μg/mL) | Ribavirin (μg/mL) |
|--------|----------------|---------------|----------------------|-------------------|
| PRK    | 0.7            | 4t            | 0.07                 | 300               |
| HeLa   | 0.1            | 2t            | 2                    | 20                |
| ESM    | 0.1            | 400t          | 0.07                 | 300               |
| HEL    | 2              | ND            | 15                   | 200               |
| Vero   | 1.5            | 100           | 0.7                  | 100               |
| RK13   | 0.1            | >400t         | 0.07                 | 300               |
| BSC-1A | 0.2            | 300t          | 0.7                  | 20                |
| GBK    | 0.4            | ND            | 0.7                  | 70                |
| CV-1   | 2              | 2t            | 70                   | 150               |
| L-929  | 0.4            | ND            | 0.4                  | 300               |

* Concentration required to reduce virus-induced cytopathogenicity by 50%. Microscopically visible alteration of normal cell morphology was not observed with Ce-Cyd or ribavirin at the highest concentration tested (400 μg/mL). With neplanocin, an alteration of normal cell morphology was observed in all lines at a concentration of ≥40 μg/mL. With C-Cyd, it was observed in ESM and CV-1 at a concentration of ≥200 μg/mL.

† Data taken from De Clercq et al. [15].
ND, not determined.

Table 4. Inhibitory effects of Ce-Cyd and neplanocin A on the growth of different tumor cell lines

| Cell   | Ce-Cyd (μg/mL) | Neplanocin A (μg/mL) |
|--------|----------------|----------------------|
| L1210  | 0.033 ± 0.001  | 0.104 ± 0.027        |
| FM3A   | 0.048 ± 0.001  | 0.0583 ± 0.0008      |
| Raji   | 0.033 ± 0.004  | 0.734 ± 0.196        |
| Molt/4F| 0.036 ± 0.008  | 1.84 ± 0.92          |
| HeLa   | 0.0056 ± 0.0009| 0.225 ± 0.110        |

Values are mean ± SD.

Table 3. Antimetabolic activity of Ce-Cyd, C-Cyd, neplanocin A and ribavirin in Vero cells

| Compound     | DNA synthesis [Methyl-3H]dThd incorporation | RNA synthesis [5-3H]Urd incorporation | Protein synthesis [4.5-3H]Leu incorporation |
|--------------|---------------------------------------------|---------------------------------------|------------------------------------------|
| Ce-Cyd       | 1.4 ± 0.6                                   | 0.7 ± 0.3                             | >100                                     |
| C-Cyd        | 0.65 ± 0.4                                  | 3.0 ± 2.5                             | >400                                     |
| Neplanocin A | 1.0 (0.5-1.7)+                              | 1.4 (0.3-3.2)+                        | 13 (7-19)+                               |
| Ribavirin    | 9 ± 6                                       | 20 ± 6.5                              | >400                                     |

Values are mean ± SD.

* Required to reduce incorporation of radiolabeled precursors by 50%.
† Data obtained for PRK cells [24]
Table 5. Reversing effect of different nucleosides on antiviral activity of Ce-Cyd

| Nucleoside | Concentration (µg/mL) | Vaccinia virus (PRK) | Vesicular stomatitis virus (HeLa) | Reo 1 virus (Vero) | Semliki forest virus (Vero) |
|------------|-----------------------|----------------------|----------------------------------|-------------------|-----------------------------|
|            |                       | 50% Inhibitory concentration* (µg/mL) |                                 |                   |                             |
| dThd       | 100                   | 0.7                  | 0.2                              | 0.4               | 0.7                         |
|            | 10                    | 0.7                  | 0.1                              | 0.1               | 0.7                         |
|            | 1                     | 0.2                  | 0.1                              | 0.1               | 0.4                         |
| Urd        | 100                   | 20                   | 2                                | 0.7               | 0.7                         |
|            | 10                    | 2                    | 0.4                              | 0.3               | 2                           |
|            | 1                     | 0.7                  | 0.07                             | 0.07              | 0.7                         |
| dCyd       | 100                   | 0.7                  | 0.1                              | 0.07              | 0.4                         |
|            | 10                    | 0.7                  | 0.07                             | 0.07              | 0.4                         |
|            | 1                     | 0.7                  | 0.07                             | 0.07              | 0.4                         |
| Cyd        | 100                   | >100                 | >100                             | >100              | >100                        |
|            | 10                    | >100                 | 4                                | 4                 | >100                        |
|            | 1                     | 4                    | 0.07                             | 0.07              | 4                           |
| None       |                       | 0.7                  | 0.1                              | 0.07              | 0.4                         |

* Required to reduce virus-induced cytopathogenicity by 50%. At the concentrations used (1, 10 and 100 µg/mL), the nucleosides dThd, Urd, dCyd and Cyd did not interfere with virus-induced cytopathogenicity.

Table 6. Reversing effect of different nucleosides on cytocidal activity of Ce-Cyd

| Nucleoside | Concentration (µg/mL) | L1210 | Vero  | HeLa |
|------------|-----------------------|-------|-------|------|
|            |                       |       |       |      |
| dThd       | 100                   | 0.0073| 0.015 | ND   |
|            | 10                    | 0.0058| 0.034 | 0.0032|
|            | 1                     | 0.0095| 0.041 | 0.0032|
| Urd        | 100                   | 3.9   | 3.4   | 4.1  |
|            | 10                    | 0.052 | 0.29  | 0.19 |
|            | 1                     | 0.016 | 0.061 | 0.0024|
| dCyd       | 100                   | 0.059 | 0.055 | 0.026|
|            | 10                    | 0.063 | 0.051 | 0.0048|
|            | 1                     | 0.021 | 0.016 | 0.0300|
| Cyd        | 100                   | >100  | >100  | >100 |
|            | 10                    | 3.3   | >10   | 0.80 |
|            | 1                     | 0.016 | 0.20  | 0.0022|
| None       |                       | 0.015 | 0.036 | 0.0036|

* Required to reduce cell proliferation (during the exponential growth phase) by 50%. At the concentrations used (1, 10 and 100 µg/mL), Urd, dCyd and Cyd did not cause any inhibition of L1210, Vero or HeLa cell growth; dThd, however, effected a 50% reduction in the growth of L1210, Vero and HeLa cells at a concentration of 20, 91 and 27 µg/mL, respectively.

ND, not determined.

Ce-Cyd on the proliferation of L1210, Vero or HeLa cells, whereas Cyd and, to a lesser extent, Urd counteracted the cytocidal activity of Ce-Cyd. At 100 µg/mL, Cyd completely reversed the inhibitory effect of Ce-Cyd on tumor cell growth; at 10 µg/mL, it effected a 200- to 300-fold increase in IC₅₀. When added at a concentration of 100 µg/mL, Urd also caused a significant (100- to 1000-fold) increase in the IC₅₀ of Ce-Cyd.

Finally, different antimetabolites that are targeted at different enzymes in nucleic acid biosynthesis [OMP decarboxylase (pyrazofurin, 6-azauridine), RNA polymerase (5-fluorouracil), S-adenosylhomocysteine hydrolase (neplanocin A), DNA polymerase (cytarabine)] were examined in conjunction with Ce-Cyd. Whereas 5-fluorouracil, neplanocin A and cytarabine did not influence the inhibitory effect of Ce-Cyd on L1210 cell growth, pyrazofurin and 6-azauridine potentiated the cytocidal activity of Ce-Cyd. All antimetabolites were
Table 7. Potentiating effect of some nucleoside analogues on the cytocidal activity of Ce-Cyd

| Nucleoside analogue added | Concentration (µg/mL) | 50% Inhibitory concentration* (ng/mL) Ce-Cyd |
|---------------------------|----------------------|---------------------------------------------|
| Pyrazofurin               | 0.1                  | 7.5 ± 2.5                                   |
|                           | 0.01                 | 16.8 ± 1.8                                  |
|                           | 0.001                | 31.3 ± 4.4                                  |
| 6-Azaauridine             | 0.1                  | 4.0 ± 1.0                                   |
|                           | 0.01                 | 19.4 ± 3.8                                  |
| 5-Fluorouracil            | 1                    | 33.1 ± 6.1                                  |
|                           | 0.1                  | 38.8 ± 8.1                                  |
|                           | 0.01                 | 39.6 ± 5.1                                  |
| Neplanocin A              | 1                    | 17.3 ± 1.4                                  |
|                           | 0.1                  | 23.0 ± 11.3                                 |
|                           | 0.01                 | 34.3 ± 1.6                                  |
| Cytarabine                | 0.1                  | 34.7 ± 8.5                                  |
|                           | 0.01                 | 47.0 ± 7.0                                  |
|                           | 0.001                | 40.6 ± 1.4                                  |
| None                      | —                    | 42.9 ± 4.2                                  |

Values are mean ± SD.

* Required to reduce L1210 cell proliferation (during the exponential growth phase) by 50%. The nucleoside analogues effected a 50% reduction in the growth of L1210 cells at the following concentrations: pyrazofurin (0.025 µg/mL), 6-azaauridine (0.034 µg/mL), 5-fluorouracil (0.32 µg/mL), neplanocin A (0.40 µg/mL), and cytarabine (0.016 µg/mL).

used at concentrations below and above their IC₅₀ for L1210 cell growth (Table 7). Under these conditions, pyrazofurin and 6-azaauridine, when added at a concentration of 0.1 µg/mL (which is above their IC₅₀ for L1210 cell growth), brought about a 6- to 10-fold decrease in the IC₅₀ of Ce-Cyd.

DISCUSSION

Various enzymes of both viral or cellular origin have been shown to interact as either activators or targets for antiviral agents. The activity spectrum of these antiviral agents is determined by the enzymes with which they interact. For example, acyclovir [9-(2-hydroxyethoxymethyl)guanine] needs to be phosphorylated by the virus-encoded thymidine kinase (TK) before it will interact, as a chain terminator, with the viral DNA polymerase [33]. Hence, acyclovir is only active against those viruses, in particular herpes simplex virus type 1 (HSV-1) and 2 (HSV-2), that encode a viral TK recognizing acyclovir as substrate. The phosphorylmethoxyalkyl derivatives, i.e. HPMPA [(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine] and HPMPC [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine], are not dependent on the viral TK for their phosphorylation, and, hence, these compounds are effective against a much broader spectrum of viruses, including TK⁻ herpesviruses and various other DNA viruses (i.e. adenov-, pox-, irido- and hepadnaviruses) [34].

Most compounds that have been recognized as selective antiviral agents interact with a specific viral protein: i.e. influenza A virus matrix (M₂) protein (amantadine) [35], HSV-1 DNA polymerase (acyclovir triphosphate) [36], HIV-1 reverse transcriptase (azidothymidine triphosphate) [37]. Yet, the target protein should not necessarily be of viral origin. Under certain conditions, host cell enzymes may serve as targets for antiviral agents. Thus, while not being a target for anti-HSV compounds in TK⁺ HSV-1-infected cells, thymidylate synthase may be an important target in TK⁻ HSV-1-infected cells [21]. Also, S-adenosylhomocysteine (SAH) hydrolase, another host cell enzyme, has been identified as a target for the broad-spectrum antiviral action of several acyclic and carbocyclic adenosine analogues [38], including neplanocin A [24], 3-deazaneplanocin A and their 5'-nor derivatives [39]. Through their inhibitory effect on SAH hydrolase these compounds enhance the intracellular levels of SAH and thus inhibit transmethylation reactions starting from S-adenosylmethionine (SAM) as the methyl donor. This includes a number of transmethylation reactions catalysed by virus-associated methyltransferases that are required for the maturation of viral mRNAs.

Like SAH hydrolase, CTP synthetase is an example of a host cell enzyme that may be envisaged as a target enzyme for antiviral agents. CTP synthetase catalyses the last step in the biosynthesis of pyrimidine ribonucleoside 5'-triphosphates, that is the conversion of UTP to CTP (Fig. 2). There is circumstantial evidence for the role of CTP synthetase as target for the cytocidal activity of Ce-Cyd. As has been demonstrated in several cell lines, i.e. murine leukemia L1210 cells [13, 14], human colon carcinoma HT-29 cells [12], human promyelocytic leukemia HL-60 cells [40] and human colon carcinoma HCT 116 cells [41], Ce-Cyd treatment leads to a marked depletion of CTP pools, and this CTP pool reduction
is closely correlated with the cytocidal activity of the compound. The depletion of CTP pools is most likely due to the inhibition of CTP synthetase, and, in fact, the triphosphates of both C-Cyd [9] and Ce-Cyd [14] have been shown to inhibit CTP synthetase. CTP pools were not measured in the host cells (i.e. PRK, HEL, Vero) used for the antiviral assays. However, we surmise that, since in all cell systems examined thus far [12-14, 40, 41] CTP pools are depleted as a consequence of Ce-Cyd treatment, this may also be the case for the cells used in the present study. At the concentrations at which Ce-Cyd was found effective in inhibiting virus-induced cytopathogenicity [for vaccinia virus, a concentration as low as 0.08 μM (Table 1)], it causes a significant reduction in CTP pools [12-14, 40, 41]. Also, the fact that exogenous addition of Cyd or Urd, but not dThd or dCyd, reverses the antiviral activity of C-Cyd [15] and Ce-Cyd (Table 5) supports the notion that the antiviral action of these cytidine analogues may be mediated by the inhibition of CTP synthetase (Fig. 2).

There are only a few compounds known to exert an antiviral effect through interference with the biosynthesis of pyrimidine ribonucleotides. Two antimetabolites that are supposed to do so are pyrazofurin [16, 17] and 6-azauridine [18]. These compounds are targeted at OMP decarboxylase (Fig. 2). Whether targeted at CTP synthetase (C-Cyd, Ce-Cyd) or OMP decarboxylase (pyrazofurin, 6-azauridine), all four compounds have antitumor, in addition to, antiviral properties. In fact, the antitumor potential of pyrazofurin [17] and Ce-Cyd [11] has been considered the more attractive for initial development of these drugs.

Why may some compounds, such as Ce-Cyd, have potential as both antitumor and antiviral agents? If viruses or tumor cells impose similar requirements on some essential metabolites for their growth, one may expect that a shortage in the supply of these metabolites leads to suppression of both virus growth and tumor cell growth. Through its inhibitory effect on CTP synthetase, Ce-Cyd abrogates the CTP supply that is needed for both virus replication and tumor cell growth. Consequently, both the antiviral and cytocidal effects of the compound are reversed if the CTP pools are restored by the exogenous addition of cytidine.

Whether Ce-Cyd has any practical utility for the treatment of virus infections in humans remains to be established. It could be argued that the antitumor and antiviral properties of Ce-Cyd may be mutually exclusive. This is certainly not the case if the antiviral and antitumor (or cytocidal) assays are conducted under different conditions, that is with resting confluent cells for the antiviral assays and exponentially growing cells for the cytocidal assays. Under these conditions, Ce-Cyd exhibits antiviral activity at concentrations which are by several orders of magnitude lower than the concentrations that are toxic to the host cells. If, however, rapidly growing cells have to be used to monitor antiviral activity, as is the case for HIV, the toxicity of the compound for the host (MT-4) cells precludes any specific action against the virus. If these considerations are extrapolated to the in vivo situation, it follows that, if Ce-Cyd were to be used as an antiviral drug, proper conditions have to be conceived so as to prevent the toxic effect of the compound on rapidly growing cells (i.e. bone marrow, small intestine). This goal may well be achieved by site-specific delivery whereby the drug is directly delivered to the site of virus infection, i.e. if the compound is administered as an aerosol in the treatment of virus infections of the respiratory tract.

Similar recommendations may be made for pyrazofurin, which also exhibits broad-spectrum antiviral activity in vitro [42], and, in addition, has proved inhibitory to the replication of respiratory syncytial virus (RSV) in vivo, in cotton rats given daily doses of 10 mg/kg [43]. Pyrazofurin may be too toxic for systemic administration, but, as an aerosol, it may prove particularly useful, not only in the treatment of RSV infection, but also in the
treatment of other respiratory tract virus infections. The high potency and wide-spectrum activity of pyrazofurin [26-28] and Ce-Cyd (Table 1) against ortho- and paramyxoviruses in vitro make these compounds attractive candidates in the pursuit of an effective chemotherapy of respiratory virus infections.

As Ce-Cyd and pyrazofurin interact with different steps of the biosynthesis of pyrimidine ribonucleotides (Fig. 2), they may act synergistically if combined. Such combinations should be pursued from both an antiviral and antitumor viewpoint. The combination of pyrazofurin with Ce-Cyd has already been examined in one tumor cell system (i.e. L1210) and in this system pyrazofurin potentiated the cytotoxic activity of Ce-Cyd.

Acknowledgements—This work was supported by grants from the Belgian Fonds voor Geneeskundig Wetenschappelijk Onderzoek (Projects No. 3.0040.83 and No. 3.0097.87), the Belgian Geconcerteerde Onderzoeksaak (Project No. 85/90-79) and the AIDS Basic Research Programme of the European Community.

We thank Anita Van Lierde, Frieda De Meyer, Ria Van Berwaer, Lizectte Van Breckelcar, Ann Absilis and Anita Camps for their excellent technical help and Christiane Callebaut for her dedicated editorial assistance.

REFERENCES

1. Shealy YF, Frye JL, DuBois NF, Shaddix SC and Brockman RW. Carbocyclic analogues of 5-fluorouracil nucleosides. J Med Chem 24: 1083-1086, 1981.
2. Shealy YF, O’Dell CA, Shannon WM and Arnett G. Carboxyclic analogues of 5-substituted uracil nucleosides: synthesis and antiviral activity. J Med Chem 26: 156-161, 1983.
3. Herdeijn P, De Clercq E, Balzarini J and Vanderhaeghe H. Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2'-deoxyuridines and (E) 5(2 halovinyl) 2'-deoxyuridylin. J Med Chem 28: 550-555, 1985.
4. Shealy YF, O’Dell CA, Arnett G and Shannon WM. Synthesis and antiviral activity of the carbocyclic analogues of 5-ethyl-2’-deoxyuridine and of 5-ethyl-2’-deoxyuridin. J Med Chem 29: 70-84, 1986.
5. Shealy YF, O’Dell CA, Shannon WM and Arnett G, Carbocyclic analogues of 5-amino-5’-deoxy- and 5’-amino-3’-deoxythymidines. J Med Chem 29: 483-488, 1986.
6. Shealy YF, O’Dell CA, Arnett G, Shannon WM, Thorpe MC, Riordan JM and Coburn WC Jr, Carbocyclic analogues of 5-halouracil nucleosides. J Med Chem 29: 720-725, 1986.
7. Borthwick AD, Evans DN, Burk BE, Biggadake K, Exall AM, Youds P, Roberts SM, Knight DJ and Coates JAV. Fluoro carboxyclic nucleosides: synthesis and antiviral activity of 2’- and 6’-fluoro carbocyclic pyrimidine nucleosides including carbocyclic 1-(2-deoxy-2-fluoro-B-D-arabinofuranosyl)-5-methyluracil and carbocyclic 1-(2-deoxy-2-fluoro-B-D-arabinofuranosyl)-5-iodouracil. J Med Chem 33: 179-186, 1990.
8. Shealy YF and O’Dell CA. Carbocyclic analogs of cytosine nucleosides. J Heterocyc Chem 17: 353-358, 1980.
9. Shannon WM, Arnett G, Westbrook L, Shealy YF, O’Dell CA and Brockman RW. Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza type A viruses. Antimicrob Agents Chemother 20: 769-776, 1981.
10. Lim M-I, Moyer JD, Cysyk RL and Marquez VE. Cyclopentenyluridine and cyclopentenylcytidine analogues as inhibitors of uridine-cytidine kinase. J Med Chem 27: 1536-1538, 1984.
11. Marquez VE, Lim M-I, Treanor SP, Fluhmann J, Priest MA, Markovac A, Khan MS, Kaskar B and Driscoll JS, Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties. J Med Chem 31: 1687-1694, 1988.
12. Glazer RJ, Knose MC, Lim M-I and Marquez VE. Cyclopentenyl cytidine analogue. An inhibitor of cytidine triphosphate synthesis in human colon carcinoma cells. Biochem Pharmacol 34: 2535-2539, 1985.
13. Moyer JD, Malinowski NM, Treanor SP and Marquez VE, Antitumor activity and biochemical effects of cyclopentenyl cytosine in mice. Cancer Res 46: 3325-3329, 1986.
14. Kang GJ, Cooney DA, Moyer JD, Kelley JA, Kim H-Y, Marquez VE and Johns DG, Cyclopentenylicytosine triphosphate. Formation and inhibition of CTP synthetase. J Biol Chem 264: 713-718, 1989.
15. De Clercq E, Bernaerts R, Shealy YF and Montgomery JA, Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine. Biochem Pharmacol 39: 319-325, 1990.
16. Ohnuma T, Roboz J, Shapiro ML and Holland JF, Pharmacological and biochemical effects of pyrazofurin in humans. Cancer Res 37: 2043-2049, 1977.
17. Cadman EC, Dix DE and Handschumacher RF, Clinical, biological, and biochemical effects of pyrazofurin. Cancer Res 38: 682-688, 1978.
18. Janeway CM and Cha S, Effects of 6-azauridine on nucleotides, arotic acid, and orotidine in L5178Y mouse lymphoma cells in vitro. Cancer Res 37: 4382-4388, 1977.
19. Saot ME, Lyons SD, Kemaj AJ, Mcclure LK, Szalvadus E and Christopherson R1, Dual effects of pyrazofurin and 3-deazauridine upon pyrimidine and urine biosynthesis in mouse L1210 leukemia. Cancer Res 49: 2645-2650, 1989.
20. De Clercq E, Descamps J, Verhelst G, Walker RT, Jones AS, Torrence PF and Shugar D, Comparative efficacy of antithelial drugs against different strains of herpes simplex virus. J Infect Dis 141: 563-574, 1980.
21. De Clercq E, Beres J and Bentrude WG, Potential activity of 5-fluro-2’-deoxyuridine and related compounds against thymidine kinase-deficient (TK-) herpes simplex virus: targeted at thymidylate synthase. Mol Pharmacol 32: 286-292, 1987.
22. Snoocek R, Sakuma T, De Clercq E, Rosenberg I and Holy A. (3)-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytidine deaminase replication. Antimicrob Agents Chemother 32: 1839-1844, 1988.
23. De Clercq E and Luczkz M, Fluororimidazoles as antiviral agents and inhibitors of polynucleotide biosynthesis. Life Sci 17: 187-194, 1975.
24. De Clercq E, Antiviral and antimebolitic activities of neplanocins. Antimicrob Agents Chemother 28: 84-89, 1985.
25. Andrei G and De Clercq E, Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Res 14: 287-300, 1990.
26. De Clercq E, Bernaerts R, Bergstrom DE, Robins MJ, Montgomery JA and Holy A, Anirhinovirus activity of purine nucleoside analogs. Antimicrob Agents Chemother 29: 482-487, 1986.
27. Kawana F, Shigeta S, Hossy M, Suzuki H and De Clercq E, Inhibitory effects of antiviral compounds
on respiratory syncytial virus replication in vitro. Antimicrob Agents Chemother 31: 1225–1230, 1987.

28. Hosoya M, Shigeta S, Nakamura K and De Clercq E, Inhibitory effect of selected antiviral compounds on measles (SSPE) virus replication in vitro. Antiviral Res 12: 87–98, 1989.

29. Shigeta S, Konno K, Yokota T, Nakamura K and De Clercq E, Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro. Antimicrob Agents Chemother 32: 906–911, 1988.

30. De Clercq E, Balzarini J, Torrence PF, Mertes MP, Schmidt CL, Shugar D, Barr PJ, Jones AS, Verhelst G and Walker RT, Thymidylate synthetase as target enzyme for the inhibitory activity of 5-substituted 2′-deoxyuridines on mouse leukemia L1210 cell growth. Mol Pharmacol 19: 321–330, 1981.

31. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT and Robins RK, Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177: 705–706, 1972.

32. De Clercq E, Cools M and Balzarini J, Homocysteine potentiates the antiviral and cytostatic activity of those nucleoside analogues that are targeted at S-adenosylhomocysteine hydrolase. Biochem Pharmacol 38: 1771–1778, 1989.

33. De Clercq E, Biochemical aspects of the selective antiviruses activity of nucleoside analogues. Biochem Pharmacol 33: 2159–2169, 1984.

34. De Clercq E, Sakuta T, Baba M, Pauwels R, Balzarini J, Rosenberg I and Holy A, Antiviral activity of phosphorylmethoxalkyl derivatives of purine and pyrimidines. Antiviral Res 8: 261–272, 1987.

35. Hay AJ, Wolstenholme AJ, Skehel JJ and Smith MH, The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4: 3021–3024, 1985.

36. Reardon JE and Spector T, Herpes simplex virus type 1 DNA polymerase. J Biol Chem 264: 7405–7411, 1989.

37. St Clair MH, Richards CA, Spector T, Weinhold KJ, Miller WH, Langlois AJ and Furman PA, 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 31: 1972–1977, 1987.

38. De Clercq E, S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem Pharmacol 36: 2567–2575, 1987.

39. De Clercq E, Cools M, Balzarini J, Marquez VE, Borcherding DR, Borchart D, Drach JC, Kitaoka S and Konno T, Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their S′-nor derivatives. Antimicrob Agents Chemother 33: 1291–1297, 1989.

40. Glazer RI, Cohen MB, Hartman KD, Knode MC, Lim M-I and Marquez VE, Induction of differentiation in the human promyelocytic leukemia cell line HL-60 by the cyclopentenyl analogue of cytidine. Biochem Pharmacol 35: 1841–1848, 1986.

41. Grem JL and Allegra CJ, Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-β-D-arabinofuranosylcytosine by cyclopentenyl cytosine. Cancer Res 50: 7279–7284, 1990.

42. Descamps J and De Clercq E, Broad-spectrum antiviral activity of pyrazofurin (pyrazomycin). In: Current Chemotherapy (Eds. Siegenthaler W and Lüthy R), pp. 354–357. American Society for Microbiology, Washington, DC, 1978.

43. Wyde PR, Gilbert BE and Ambrose MW, Comparison of the anti-respiratory syncytial virus activity and toxicity of papaverine hydrochloride and pyrazofurin in vitro and in vivo. Antiviral Res 11: 15–26, 1989.